EXELIXIS, INC.

EXEL · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
139
SEC Filings

Business Summary

Exelixis, Inc. is a oncology-focused biopharmaceutical company that discovers, develops, and commercializes cancer treatments. The company's key marketed product is cabozantinib, sold under the brand names Cabometyx and Cometriq, approved for renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. Exelixis also has a pipeline of additional oncology compounds in clinical development.

Next Earnings

Q2 FY2026 — expected 2026-08-20

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionEXELdiscussed_in_filing Cybersecurity
topic_mentionEXELdiscussed_in_filing Trusted Computing
topic_mentionEXELdiscussed_in_filing Blockchain & Crypto
topic_mentionEXELdiscussed_in_filing Regulation
topic_mentionEXELdiscussed_in_filing Healthcare & Bio
topic_mentionEXELdiscussed_in_filing Sovereign & Government
topic_mentionEXELdiscussed_in_filing Cybersecurity
topic_mentionEXELdiscussed_in_filing Trusted Computing
topic_mentionEXELdiscussed_in_filing Blockchain & Crypto
topic_mentionEXELdiscussed_in_filing Regulation
topic_mentionEXELdiscussed_in_filing Healthcare & Bio
topic_mentionEXELdiscussed_in_filing Sovereign & Government
topic_mentionEXELdiscussed_in_filing Cybersecurity
topic_mentionEXELdiscussed_in_filing Trusted Computing
topic_mentionEXELdiscussed_in_filing Blockchain & Crypto
topic_mentionEXELdiscussed_in_filing Regulation
topic_mentionEXELdiscussed_in_filing Healthcare & Bio
topic_mentionEXELdiscussed_in_filing Sovereign & Government
topic_mentionEXELdiscussed_in_filing Cybersecurity
topic_mentionEXELdiscussed_in_filing Trusted Computing

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-102026-01-020000939767-26-000021EDGAR46K words
2025-02-112025-01-030000939767-25-000019EDGAR—
2024-02-062023-12-290000939767-24-000028EDGAR—
2023-02-072022-12-300000939767-23-000019EDGAR—
2022-02-182021-12-310000939767-22-000026EDGAR—
2021-02-112021-01-010001628280-21-001852EDGAR—
2020-02-252020-01-030000939767-20-000035EDGAR—
2019-02-222018-12-280000939767-19-000042EDGAR—
2018-02-262017-12-290000939767-18-000023EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-042025-10-030000939767-25-000128EDGAR26K words
2025-07-282025-07-040000939767-25-000113EDGAR—
2025-05-132025-04-040000939767-25-000075EDGAR—
2024-10-292024-09-270000939767-24-000150EDGAR—
2024-08-062024-06-280000939767-24-000119EDGAR—
2024-04-302024-03-290000939767-24-000058EDGAR—
2023-11-012023-09-290000939767-23-000114EDGAR—
2023-08-012023-06-300000939767-23-000079EDGAR—
2023-05-092023-03-310000939767-23-000048EDGAR—
2022-11-012022-09-300000939767-22-000110EDGAR—
2022-08-092022-07-010000939767-22-000097EDGAR—
2022-05-102022-04-010000939767-22-000058EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-02-100000939767-26-000019EDGAR5K words
2026-01-120000939767-26-000003EDGAR—
2025-11-070000939767-25-000133EDGAR—
2025-11-040000939767-25-000127EDGAR—
2025-08-290000939767-25-000115EDGAR—
2025-07-280000939767-25-000111EDGAR—
2025-06-020000939767-25-000097EDGAR—
2025-05-130000939767-25-000074EDGAR—
2025-03-310000939767-25-000049EDGAR—
2025-02-210000939767-25-000032EDGAR—

139 total filings indexed. 108 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Tags

oncology biopharmaceuticals

Company Identity

CIK0000939767
TickerEXEL
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 521f0ef4de859aee3e495b2e23309eb6a6b13074fa674fe5949f47817e89381d
parent: 979b5183019ac22e02f6d8953803076169e3f720c79a7ae147f1a2e9508ffd3b
content hash: e13ecd7bbbb9d84896e9a513b66fc4e32a90e07c4a1b9b0fe09103e977280210
signed: 2026-04-13T04:44:57.666Z
sources: 21 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf